Qurient Co. Ltd. and TB Alliance announced that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections. Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license (except for South Korea, Russia and the Commonwealth of Independent States (CIS) countries) to develop and commercialize telacebec for the treatment of tuberculosis and some non-tuberculosis mycobacteria (NTM) infections.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,690 KRW | -0.14% |
|
-0.54% | -20.99% |
1st Jan change | Capi. | |
---|---|---|
-20.99% | 87.47M | |
+29.50% | 77.77B | |
+0.30% | 24.62B | |
+14.70% | 8.75B | |
+0.73% | 8.35B | |
-28.87% | 7.1B | |
+16.06% | 5.25B | |
+1.58% | 4.1B | |
-8.90% | 3.8B | |
-7.62% | 3.39B |
- Stock Market
- Equities
- A115180 Stock
- News Qurient Co., Ltd.
- Qurient Co. Ltd. and TB Alliance Announces Exclusive License Agreement for Telacebec